Latham & Watkins has advised Centerview Partners as lead financial advisor to MorphoSys AG in connection with the business combination agreement with Novartis data42 AG and Novartis AG (Novartis).
Based on the business combination agreement, Novartis will submit a voluntary public takeover offer for all of MorphoSys' outstanding common shares and offer MorphoSys' shareholders €68.00 per share in cash, for a total equity value of €2.7 billion. The takeover offer will contain customary closing conditions, in particular a minimum acceptance threshold and regulatory clearances. The closing is currently expected to take place in the first half of 2024. MorphoSys and Novartis agreed to take MorphoSys private promptly after the takeover offer has been settled.
The Latham team was led by Orange County partner Scott Shean and Düsseldorf partner Heiko Gotsche, with associates Brian Umanoff and Steffen Augschill.